Prostate xenografts in SRG Rat

[fusion_builder_container hundred_percent=”yes” overflow=”visible”][fusion_builder_row][fusion_builder_column type=”1_1″ last=”yes” spacing=”yes” center_content=”no” hide_on_mobile=”no” background_color=”” background_image=”” background_repeat=”no-repeat” background_position=”left top” border_position=”all” border_size=”0px” border_color=”” border_style=”” padding=”” margin_top=”” margin_bottom=”” animation_type=”” animation_direction=”” animation_speed=”0.1″ class=”” id=””][fusion_text]

SRG rats™ enable the VCaP prostate carcinoma xenograft model

[/fusion_text][/fusion_builder_column][fusion_builder_column type=”1_1″ last=”yes” spacing=”yes” center_content=”no” hide_on_mobile=”no” background_color=”” background_image=”” background_repeat=”no-repeat” background_position=”left top” border_position=”all” border_size=”0px” border_color=”” border_style=”” padding=”” margin_top=”” margin_bottom=”” animation_type=”” animation_direction=”” animation_speed=”0.1″ class=”” id=””][fusion_text]VCaP is a prostate cancer cell line that exhibits many of the characteristics of clinical prostate carcinoma, including expression of PSA, PAP, and AR. VCaP cells also express retinoblastoma (Rb) and p53 (with a A248W mutation). The VCaP model is known to have poor engraftment rates and kinetics in immunodeficient mice (i.e. nude mice, SCID mice, NSG mice), making it challenging to generate a cohort of animals with similar tumor sizes for an efficacy study. High tumor take rates (> 70%) in SRG rats reduces the total animals required which, along with larger sample sizes, save time and money.[/fusion_text][fusion_text]

SRG rat VCaP products & services

[fusion_checklist icon=”fa-check” iconcolor=”#81d742″ circle=”no” circlecolor=”” size=”13px” class=”” id=””]
[fusion_li_item icon=””] SRG rats off-the-shelf for engraftment at the customers facility[/fusion_li_item]
[fusion_li_item icon=””]Pre-implanted SRG rats delivered to customer[/fusion_li_item]
[fusion_li_item icon=””]Xenograft efficacy CRO services at Hera BioLabs[/fusion_li_item]
[/fusion_checklist][/fusion_text][/fusion_builder_column][fusion_builder_column type=”1_1″ last=”yes” spacing=”yes” center_content=”no” hide_on_mobile=”no” background_color=”” background_image=”” background_repeat=”no-repeat” background_position=”left top” border_position=”all” border_size=”0px” border_color=”” border_style=”” padding=”” margin_top=”” margin_bottom=”” animation_type=”” animation_direction=”” animation_speed=”0.1″ class=”” id=””][fusion_text]

VCaP Tumor Kinetics in SRG rats

[/fusion_text][fusion_text][/fusion_text][fusion_separator style_type=”none” top_margin=”7″ bottom_margin=”” sep_color=”” border_size=”” icon=”” icon_circle=”” icon_circle_color=”” width=”” alignment=”center” class=”” id=””/][fusion_text]VCaP cancer cells have dismal engraftment rates and kinetics in immunodeficient mice, but thrived in the SRG rat. The cells were inoculated in the flank region at a density of 10e6 cells per rat in a 1:1 solution of cell culture media and 5mg/ml Cultrex. Engraftment rate was 75%. Each line represents growth in a single animal.[/fusion_text][/fusion_builder_column][fusion_builder_column type=”1_1″ last=”yes” spacing=”yes” center_content=”no” hide_on_mobile=”no” background_color=”” background_image=”” background_repeat=”no-repeat” background_position=”left top” border_position=”all” border_size=”0px” border_color=”” border_style=”” padding=”” margin_top=”” margin_bottom=”” animation_type=”” animation_direction=”” animation_speed=”0.1″ class=”” id=””][fusion_text]

Drug efficacy in VCaP in SRG rats